Immune Checkpoint Inhibitors Combined With Radiotherapy in Metastatic Melanoma: Impact on Overall Survival and Tumor Control
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Metastatic melanoma is an aggressive malignancy characterized by a high mutational burden that confers strong intrinsic immunogenicity, enabling recognition by the host immune system. This biological feature has positioned immune checkpoint inhibitors as a cornerstone of modern melanoma therapy, leading to significant improvements in survival outcomes. Nevertheless, durable responses remain limited by immune evasion mechanisms, intratumoral heterogeneity, and the development of primary or acquired resistance. In this context, radiotherapy has emerged as a relevant immunomodulatory strategy rather than a purely local or palliative treatment. Beyond its cytotoxic effects, radiotherapy promotes immunogenic cell death, enhances tumor antigen release, and induces remodeling of the tumor microenvironment, thereby potentiating systemic antitumor immune responses.The combination of radiotherapy with immune checkpoint inhibitors is supported by a strong biological rationale and growing clinical evidence. Preclinical and clinical studies demonstrate that this approach can amplify T-cell activation, facilitate antigen presentation, and promote systemic immune effects such as the abscopal phenomenon. Clinically, combined therapy has been associated with higher objective response rates, improved progression-free survival, and enhanced local and systemic tumor control compared with immunotherapy alone, particularly in challenging scenarios such as brain metastases or resistance to anti–PD-1 monotherapy. While short-term overall survival benefits remain less consistent, longer-term disease control suggests meaningful therapeutic synergy.Treatment efficacy is influenced by several factors, including the timing of radiotherapy relative to immunotherapy, radiation dose and fractionation, irradiated tumor volume, and patient-specific immunological characteristics. Although combined treatment is associated with a high incidence of immune-related adverse events, available evidence indicates that toxicity remains manageable and does not significantly exceed that observed with immunotherapy alone when appropriate monitoring is applied.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Cutaneous Melanoma Detection and Management
Brain Metastases and Treatment
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 28 March 2026
- Language
- EN